ZP2

Across TCGA pan-cancer cohorts, ZP2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ZP2 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ZP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZP2 expression acts as an unfavorable survival marker.

BLCA, LIHC, and SCLC are the cancer types where ZP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.082	0.688	<.001	24	view →
LIHC	DFS	Median	All	0.072	0.555	<.001	12	view →
SCLC	DFS	Median	II,III,IV	0.137	0.562	.013	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
SKCM	DFS	Median	All	0.101	0.214	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ZP2–BLCA (OS)

Open the BLCA breakdown →